Factors related to increasing prevalence of resistance to ciprofl oxacin and other antimicrobial drugs in Neisseria gonorrhoeae, United States

Emerging Infectious Diseases

Volumn 18, Issue 8, 2012, Pages 1290-1297

  Goldstein, Edward ^a   Kirkcaldy, Robert D ^b   Reshef, David ^c   Berman, Stuart ^b   Weinstock, Hillard ^b   Sabeti, Pardis ^d   Del Rio, Carlos ^e   Hall, Geraldine ^f   Hook, Edward W ^g,h   Lipsitch, Marc ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d HARVARD UNIVERSITY   (United States)

^e EMORY UNIVERSITY   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h Jefferson County Department of Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; GONORRHEA; HETEROSEXUAL MALE; HUMAN; MALE; MALE HOMOSEXUAL; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; PHENOTYPE; PREVALENCE; SEXUAL ORIENTATION; TRAVEL; UNITED STATES;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FEMALE; GONORRHEA; HETEROSEXUALITY; HOMOSEXUALITY, MALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; PREVALENCE; RISK FACTORS; SENTINEL SURVEILLANCE; TRAVEL; UNITED STATES;

EID: 84864476648     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1808.111202     Document Type: Article

References (26)

1. Centers for Disease Control and Prevention. Gonococcal Isolate Surveillance Project annual report. 2007 [cited 2012 May 22]. http://www.cdc.gov/std/gisp2007/GISPSurvSupp2007Complete.pdf
2. Fox KK, Whittington WL, Levine WC, Moran JS, Zaidi AA, Nakashima AK. Gonorrhea in the United States, 1981-1996. Demographic and geographic trends. Sex Transm Dis. 1998;25:386-93. http://dx.doi.org/10.1097/00007435-199808000-00011
3. Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother. 2009;10:555-77. http://dx.doi.org/10.1517/14656560902731993.
4. Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med. 2008;148:606-13.
5. Centers for Disease Control and Prevention. 1993 sexually transmitted diseases treatment guidelines. MMWR Recomm Rep. 1993;42(RR-14):1-102.
6. Borgen K, van Loo I, Koedijk F, van de Laar M. Increase of gonococcal quinolone resistance in the Netherlands from 2002-2004. Euro Surveill. 2005;10:E0511174.
7. Fenton KA, Ison C, Johnson AP, Rudd E, Soltani M, Martin I, et al. Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002. Lancet. 2003;361:1867-9. http://dx.doi.org/10.1016/S0140-6736(03)13489-7
8. Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae-Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep. 2002;51:1041-4.
9. Tapsall JW, Limnios EA, Murphy D. Analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997-2006. J Antimicrob Chemother. 2008;61:150-5. http://dx.doi.org/10.1093/jac/dkm434
10. Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. 2007;56:332-6.
11. Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009;22:87-91. http://dx.doi.org/10.1097/QCO.0b013e328320a836
12. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis. 2007;44(Suppl 3):S84-101. http://dx.doi.org/10.1086/511422
13. Lindberg R, Fredlund H, Nicholas R, Unemo M. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother. 2007;51:2117-22. http://dx.doi.org/10.1128/AAC.01604-06
14. de Vries HJ, van der Helm JJ, Schim van der Loeff MF, van Dam AP. Multidrug-resistant Neisseria gonorrhoeae with reduced cefotaxime susceptibility is increasingly common in men who have sex with men, Amsterdam, the Netherlands. Euro Surveill. 2009;14:pii:19330.
15. Schwarcz SK, Zenilman JM, Schnell D, Knapp JS, Hook EW III, Thompson S, et al. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project. JAMA. 1990;264:1413-7. http://dx.doi.org/10.1001/jama.1990.03450110059027
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 2010. Wayne (PA): The Institute; 2010.
17. Lipsitch M. The rise and fall of antimicrobial resistance. Trends Microbiol. 2001;9:438-44. http://dx.doi.org/10.1016/S0966-842X(01)02130-8
18. Little RJA, Rubin DB. Statistical analysis with missing data. 2nd ed. Hoboken (NJ): Wiley; 2002. p. xv.
19. Tapsall J. Multidrug-resistant Neisseria gonorrhoeae. CMAJ. 2009;180:268-9. http://dx.doi.org/10.1503/cmaj.081721
20. Health Protection Agency. The Gonococcal Resistance to Antimicrobials Surveillance Programme: annual report, 2007 [cited 2012 May 22]. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1221117895841
21. Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG. Changing epidemiologic profile of quinolone-resistant Neisseria gonorrhoeae in London. J Infect Dis. 2005;192:1191-5. http://dx.doi.org/10.1086/444429
22. Pérez-Losada M, Crandall KA, Bash MC, Dan M, Zenilman J, Viscidi RP. Distinguishing importation from diversification of quinoloneresistant Neisseria gonorrhoeae by molecular evolutionary analysis. BMC Evol Biol. 2007;7:84. http://dx.doi.org/10.1186/1471-2148-7-84
23. Centers for Disease Control and Prevention. GISP profiles, 2009. [cited 2012 May 22]. http://www.cdc.gov/std/gisp2009/default.htm
24. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118:259-68. http://dx.doi.org/10.1016/j.am-jmed.2004.09.015
25. Kent CK, Chaw JK, Wong W, Liska S, Gibson S, Hubbard G, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis. 2005;41:67-74. http://dx.doi.org/10.1086/430704
26. Tanaka M, Nakayama H, Huruya K, Konomi I, Irie S, Kanayama A, et al. Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone susceptibility that shows a multidrug-resistant phenotype. Int J Antimicrob Agents. 2006;27:20-6. http://dx.doi.org/10.1016/j.ijantimicag.2005.08.021